Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson executed sales of company common stock on April 8, 2026, disposing of a total of 20,000 shares for aggregate proceeds of approximately $1.65 million. According to the filings, the trades were carried out in multiple transactions with execution prices ranging from $82.48 to $85.00 per share.
The reported sales were split across three separate transactions. The largest of the three involved 17,800 shares, followed by a 2,000-share sale and a 200-share sale. The company’s shares were trading near their 52-week high of $88.35 at the time of the transaction, after a notable 171% increase in the prior 12 months.
These dispositions were made pursuant to a Rule 10b5-1 trading plan that Henderson adopted on August 13, 2025. After completing the reported sales, Henderson’s direct ownership in Apogee Therapeutics stood at 1,132,987 shares.
Valuation and market context
Apogee Therapeutics carries a market capitalization of $6.39 billion. InvestingPro analysis cited in the filings characterizes the company as currently appearing overvalued. The investing service also advertises additional proprietary tips and financial metrics for subscribers seeking deeper analysis.
Recent capital markets activity
In separate corporate finance activity, Apogee Therapeutics completed an underwritten public offering of 5.75 million common shares at $70.00 per share, which raised about $403 million in gross proceeds. That offering included the full exercise of underwriters’ option to purchase an additional 750,000 shares. The company stated it expects net proceeds of approximately $377.4 million after deducting offering expenses, completed under an effective shelf registration statement.
Additionally, the company priced a $350 million stock offering at $70 per share, with the closing scheduled for March 26, 2026.
Analyst commentary
On the research front, BTIG reiterated a Buy rating on Apogee Therapeutics with a $137 price target following the company’s presentation of 52-week APEX Part A results at the AAD conference. Mizuho raised its price target on Apogee shares to $110 from $105 while maintaining an Outperform rating. Mizuho’s adjustment followed the presentation of 52-week data for zumilokibart in atopic dermatitis and the recent follow-on offering; the firm increased its probability of success in atopic dermatitis by 10% based on the new data.
What this means
The reported insider sales occurred under an established trading plan and coincided with significant corporate financing and analyst coverage events. The filings provide quantified details on execution prices, transaction sizes, post-sale holdings, and recent capital raising actions, allowing investors to assess the transactions within the context of the company’s recent market moves and analyst adjustments.